Navigation Links
Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board
Date:4/7/2009

CAMBRIDGE, Mass., April 7 /PRNewswire/ -- Gene Network Sciences, Inc. today announced that it named Dr. Eric Schadt, a leading researcher in the field of genomics-driven drug discovery, co-chair of its Scientific Advisory Board.

Dr. Schadt will be leaving his position as Executive Scientific Director of Genetics at pharmaceutical giant Merck to join forces with the departing head of Merck oncology, Dr. Stephen Friend, to create Sage, an open-access distributed data platform designed to enable collaboration by integrating the myriad of genomic data sets in the public and private domains. At Merck's Rosetta subsidiary, Dr. Schadt founded the Genetics department. His work at Merck focused on elucidating the genetic circuitry of common human diseases such as type 2 diabetes and obesity using novel integrative genomics approaches based on genetic and molecular profiling data. He has helped define a new field in network biology -- the genetics of gene expression, or "integrative genomics." Dr. Schadt's pioneering work in integrative genomics has been published in a series of groundbreaking papers, culminating in two seminal Nature papers in 2008 that revealed the genetic circuitry underlying obesity and metabolic disease.

Dr. Schadt is also an Affiliate Professor in the Department of Biostatistics at the University of Washington in Seattle, and he was recently appointed as a Fellow in the Institute of Synthetic and Systems Biology at Imperial College London. Prior to joining Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.S. in applied mathematics/computer science from California Polytechnic State University, his M.A. in pure mathematics from UCD, and his Ph.D. in bio-mathematics from UCLA.

"I am looking forward to the opportunity to assist GNS in their efforts to accelerate the medical impact that is starting to be reaped from the emerging field of integrative genomics," said Dr. Schadt. "Among biosimulation companies, GNS's REFS(TM) platform is the best available technology to turn integrative genomics data into actionable knowledge for drug discovery and development."

Dr. Schadt will join renowned computational biologist Dr. James Collins of Boston University to serve together as co-chairs of GNS's Scientific Advisory Board.

"We are pleased to welcome the world's leading expert on the application of integrative genomics in pharmaceutical drug discovery," said Colin Hill, CEO of GNS. "The addition of Dr. Schadt to our Scientific Advisory Board exemplifies GNS's commitment to bring together the best scientific minds and technology to use supercomputer-driven modeling and simulation approaches to transform drug discovery and development and bring breakthrough treatments to patients in need."

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and healthcare settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial and treatment option. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products and the matching of patients to the optimal therapy.


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Medtronic Foundation Awards Fourth Grant to the National Parkinson Foundations National Parkinson Care Network Program
2. Companion Benefit Alternatives Awarded Silver Honors for Best Practices in Health Plans and Health Networks by URAC
3. Harris Corporation Awarded Follow-on Contract Option to Expand CONNECT Solution for Nationwide Health Information Network
4. Social Security Administration First to Go Live With CONNECT Solution for Nationwide Health Information Network
5. Harris Corporation Awarded $14 Million Contract to Develop Multi-Hospital Military Health System Network with Image-Sharing Capabilities
6. CONNECT Solution for Nationwide Health Information Network Released For General Availability by U.S. Government
7. UltraRAD and StructuRad Add Valor Network, Inc. to Client Roster
8. Interactive Autism Network opens its doors to adults with autism
9. Innovation and Sharing of Client Successes Highlight GetWellNetworks GetConnected2009 Conference
10. If You Treated an Illinois Workers Compensation Patient or a Patient Covered by an Illinois Automobile Insurance Policy and Your Bill was Reduced by a Discount Pursuant to a First Health or CCN PPO Network, Please Read This Notice Carefully As It Affects
11. Golub Capital Provides Debt Financing to Support the Acquisition of Network Express, Inc., by Ace Expediters, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: